EUVIMEDObjevte EUVIMED
Open access

EphA2-targeted alpha-particle theranostics for enhancing PDAC treatment

Ajay Kumar Sharma, Kuldeep Gupta, Akhilesh Mishra, Gabriela Lofland, Sophia Y Chen, Ian Marsh, Peyton T Fair, Robert F Hobbs, Todd M Armstrong, Elizabeth M Jaffee, Edward W Gabrielson, Lei Zheng and 1 more

Theranostics · 2025-03-18 · 15 (10) · 4229-4246

DOI: 10.7150/thno.106948 ↗

At a glance

Journal article in Theranostics, published on 2025-03-18. Written by Ajay Kumar Sharma and 12 co-authors. Institution: The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA. Major MEDLINE topics: Receptor, EphA2, Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal, Theranostic Nanomedicine. Cited 20 times so far (Crossref). The full text is freely available in PubMed Central. Funded by: NCI NIH HHS.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background

Pancreatic ductal adenocarcinoma (PDAC) presents a formidable challenge in oncology due to its aggressive nature and resistance to therapy. Current treatments, including surgery, chemotherapy, and radiotherapy, have limited success in improving patient outcomes. This study addresses the urgent need for novel radiotheranostic strategies for PDAC by investigating EphA2 as a potential target. Methods and Results: Analysis of genomic data from the Cancer Cell Line Encyclopedia (CCLE) and The Cancer Genome Atlas (TCGA) revealed elevated EphA2 expression in PDAC, confirmed by immunohistochemical staining of tumor tissue microarrays (TMAs). Further analysis showed variable EphA2 expression across PDAC cell lines, with surface receptor density not always correlating with mRNA levels. A low molecular weight peptide was developed and labeled with gallium-68 for PET imaging. In vitro studies demonstrated specific binding to EphA2-expressing PDAC cells with rapid internalization. In vivo PET imaging in subcutaneous and orthotopic PDAC models confirmed high tumor uptake and minimal off-target binding, confirming EphA2 as a valid imaging target. For molecular radiotherapy, a DOTA-conjugated peptide was labeled with the alpha-particle emitter, actinium-225. In vitro studies revealed dose-dependent cytotoxicity in PDAC cells, with an IC50 of 0.32 µCi/mL. In a tumor model, treatment with Ac-225 labeled peptide significantly inhibited tumor growth compared to controls, with mild adverse effects.

Conclusion

These results establish EphA2 as a promising radiotheranostic target in PDAC, with potential for both non-invasive imaging and targeted radiotherapy. Given the potential, further optimization of EphA2-targeted agents are warranted to advance personalized treatment strategies for PDAC patients.

Subjects

MeSH terms (MEDLINE)

Receptor, EphA2Pancreatic NeoplasmsCarcinoma, Pancreatic DuctalTheranostic NanomedicineAlpha ParticlesHumansAnimalsCell Line, TumorMicePositron-Emission TomographyXenograft Model Antitumor AssaysGallium RadioisotopesRadiopharmaceuticalsMice, NudePrecision Medicine

Author keywords

Alpha-particle therapyGallium-68ImagingPETPancreatic cancerPeptide radiopharmaceuticalsRadiotherapy

Substances

Receptor, EphA2EPHA2 protein, humanGallium RadioisotopesRadiopharmaceuticalsGallium-68

Authors and institutions

  • The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
  • Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center and the Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
  • Department of Pathology and Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
  • Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
  • Division of Clinical Pharmacology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.

Funding

  • NCI NIH HHS

Cite

APA

Sharma, A. K., Gupta, K., Mishra, A., Lofland, G., Chen, S. Y., Marsh, I., Fair, P. T., Hobbs, R. F., Armstrong, T. M., Jaffee, E. M., Gabrielson, E. W., Zheng, L., & Nimmagadda, S. (2025). EphA2-targeted alpha-particle theranostics for enhancing PDAC treatment. Theranostics, 15(10), 4229-4246. https://doi.org/10.7150/thno.106948

Vancouver

Sharma AK, Gupta K, Mishra A, Lofland G, Chen SY, Marsh I, et al. EphA2-targeted alpha-particle theranostics for enhancing PDAC treatment. Theranostics. 2025;15(10):4229-4246. doi:10.7150/thno.106948

BibTeX
@article{Sharma2025,
  author = {Sharma, Ajay Kumar and Gupta, Kuldeep and Mishra, Akhilesh and Lofland, Gabriela and Chen, Sophia Y and Marsh, Ian and Fair, Peyton T and Hobbs, Robert F and Armstrong, Todd M and Jaffee, Elizabeth M and Gabrielson, Edward W and Zheng, Lei and Nimmagadda, Sridhar},
  title = {EphA2-targeted alpha-particle theranostics for enhancing PDAC treatment},
  journal = {Theranostics},
  year = {2025},
  volume = {15},
  number = {10},
  pages = {4229--4246},
  doi = {10.7150/thno.106948}
}
Start for free →